|
APOBEC3B
|
0.400 |
Biomarker
|
group |
BEFREE |
A CCR2 antagonist suppressed TAMs and MDSCs infiltration and delayed tumour growth in A3B and A3B<sup>E68Q/E255Q</sup>- expressing mouse tumours.
|
31154396 |
2019 |
|
APOBEC3B
|
0.400 |
Biomarker
|
group |
BEFREE |
Taken together, UNG-initiated base excision repair is a major mechanism counteracting genomic mutagenesis by A3B, and blocking UNG is a potential strategy for inducing the selective death of tumors.
|
31611371 |
2019 |
|
APOBEC3B
|
0.400 |
Biomarker
|
group |
BEFREE |
We evaluated APOBEC3B expression in GEP-NENs and investigated the relationships among the immunoreactivity of APOBEC3B, clinical and pathologic features, such as age, sex, tumor site, Ki67 cell proliferation index, and lymph metastasis.
|
30095460 |
2019 |
|
APOBEC3B
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Using data from 10 cancer types generated as part of TCGA, we performed integrative genomic and association analyses to assess inter-relationship of expressions for isoforms APOBEC3A and APOBEC3B, APOBEC-mutational signature, germline APOBEC3A/B deletions, neoantigen loads, and tumor infiltration lymphocytes (TILs).
|
31533728 |
2019 |
|
APOBEC3B
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Upon clinicopathological correlation, higher A3B expression was associated with more aggressive tumor behavior.
|
30575099 |
2019 |
|
APOBEC3B
|
0.400 |
Biomarker
|
group |
BEFREE |
Taken together, the results suggest that A3B constitutively mutates the tumour genome beyond the protection of the DNA repair system, which may lead to clonal evolution and genomic instability in myeloma.
|
31073151 |
2019 |
|
APOBEC3B
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation.
|
31165764 |
2019 |
|
APOBEC3B
|
0.400 |
Biomarker
|
group |
BEFREE |
Among these, APOBEC3B contributes to tumor progression in a variety of types of tumor, including breast cancer.
|
30226610 |
2018 |
|
APOBEC3B
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Tumor size (P = 0.011), ER (P ≤ 0.0001), HER2 (P = 0.0013) and APOBEC3B expression (P = 0.037) were independent predictive factors for pCR in multivariate analysis.
|
30093965 |
2018 |
|
APOBEC3B
|
0.400 |
AlteredExpression
|
group |
BEFREE |
APOBEC3B (A3B) deamination activity on ssDNA is considered a contributing factor to tumor heterogeneity and drug resistance in a number of human cancers.
|
30130388 |
2018 |
|
APOBEC3B
|
0.400 |
Biomarker
|
group |
BEFREE |
An intimate understanding of this interaction may also lead to a novel cancer therapy because, for instance, creating a derivative of SIV<sub>mac239</sub> Vif that specifically targets human APOBEC3B could be used to suppress tumor genomic DNA mutagenesis by this enzyme, slow ongoing tumor evolution, and help prevent poor clinical outcomes.
|
29618650 |
2018 |
|
APOBEC3B
|
0.400 |
AlteredExpression
|
group |
BEFREE |
However, regarding ER-negative primary tumors, only loco-regional lymph node metastases showed increased APOBEC3B expression when compared to the corresponding primary tumor (P = 0.028).
|
28141868 |
2017 |
|
APOBEC3B
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Elevated APOBEC3B expression in tumours correlates with a kataegic pattern of localised hypermutation.
|
28535155 |
2017 |
|
APOBEC3B
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Analysis of tumour samples from women of European descent has shown that germline APOBEC3B deletion is associated with an increased propensity to develop somatic mutations and with an enrichment for immune response-related gene sets.
|
27233495 |
2016 |
|
APOBEC3B
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Evaluation of A3B expression in tumor may be a marker for breast cancer with malignant potential.
|
26476745 |
2016 |
|
APOBEC3B
|
0.400 |
Biomarker
|
group |
BEFREE |
These studies combine to indicate that APOBEC3B promotes drug resistance in breast cancer and that inhibiting APOBEC3B-dependent tumor evolvability may be an effective strategy to improve efficacies of targeted cancer therapies.
|
27730215 |
2016 |
|
APOBEC3B
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The TP53 gene was more frequently mutated in the tumors with high APOBEC3B mRNA expression.
|
27977754 |
2016 |
|
APOBEC3B
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These data link oncogene, loss of tumour suppressor gene and drug-induced replication stress with APOBEC3B activity, providing new insights into how cytidine deaminase-induced mutagenesis might be activated in tumourigenesis and limited therapeutically.
|
27634334 |
2016 |
|
APOBEC3B
|
0.400 |
Biomarker
|
group |
CTD_human |
An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.
|
26258849 |
2015 |
|
APOBEC3B
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The expression of APOBEC3B in tumor or non-tumor tissue was not found to be a risk factor of recurrence in patients with HCC.
|
25750306 |
2015 |
|
APOBEC3B
|
0.400 |
AlteredExpression
|
group |
BEFREE |
By revealing how APOBEC3B is upregulated in many cancers, our findings suggest that PKC and NF-κB inhibitors may be repositioned to suppress cancer mutagenesis, dampen tumor evolution, and decrease the probability of adverse outcomes, such as drug resistance and metastasis.
|
26420215 |
2015 |
|
APOBEC3B
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Furthermore, APOBEC3B expression was associated with gender, tumor size, histological grade, T stage, and TNM staging of the patients with gastric cancer.
|
26191203 |
2015 |
|
APOBEC3B
|
0.400 |
Biomarker
|
group |
BEFREE |
One emerging mechanism fueling tumor diversity and subclonal evolution is genomic DNA cytosine deamination catalyzed by APOBEC3B and at least one other APOBEC family member.
|
26091828 |
2015 |
|
APOBEC3B
|
0.400 |
Biomarker
|
group |
BEFREE |
APOBEC3B may also be a candidate for therapeutic targeting because inhibition of this non-essential enzyme is predicted to decrease tumor mutation rates and diminish the likelihood of undesirable mutation-dependent outcomes such as recurrence, metastasis, and the development of therapy resistant tumors.
|
25848704 |
2015 |
|
APOBEC3B
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Tumours that express high levels of APOBEC3B have twice as many mutations as those that express low levels and are more likely to have mutations in TP53.
|
23389445 |
2013 |